Ronnie Miller, President & CEO of Roche Canada, shares the lessons learnt over his 17 years heading the affiliate, the interesting dynamics and developments within the Canadian healthcare space, Roche’s significant R&D footprint in Canada, and his focus on developing Roche Canada’s multiple sclerosis, hemophilia and neuroscience portfolios over the next few years.
As a veteran of the Canadian pharma industry having headed Roche’s Canadian affiliate for 17 years now, how would you characterize the current moment in Canada’s healthcare and life sciences industry?
"The advantage Roche has is that as a brand and as a company, we are seen as the company to speak to about personalized healthcare because we have promoted this concept for so many years now."
